The short-term reliability of patient reported symptoms as a marker of atrial tachyarrhythmia or atrial fibrillation (AT/AF) recurrence has been studied. However, the long-term correlation of symptoms with continuous monitoring of AT/AF episodes during pacing is unknown. Methods: This prospective multicenter trial assessed the development of AT/AF in paced patients by examining the correlation of patient-reported symptoms with device-detected AT/AF event data in patients with bradyarrhythmias and > 1 episode of AT/AF in the prior year. Full disclosure device datalogs with electrogram (EGM) validation of AT/AF events were obtained from a pacemaker (AT500, Medtronic) that records the daily frequency, atrial and ventricular cycle length, EGM, and duration of AT/AF episodes. Patients logged symptomatic events into the device memory via an external manual activator. Following a one-month lead-in period, patients were followed for an additional 12 months and were contacted weekly to ensure compliance with activator usage. Episodes were classified as symptomatic AT/AF, asymptomatic AT/AF, or symptomatic "non-AT/AF" depending on concordance between patient-indicated symptoms and device-detected AT/AF. Results: 48 patients (28 M, 76±10 yr) were implanted and followed for 12±2 months. Arrhythmia-related symptoms were noted in 8% of all device-detected AT/AF episodes (sensitivity).Only 19% of all patient symptoms were associated with device documented AT/AF events (positive predictive value). A paired analysis in a subset of patients (n=15) with both symptomatic and asymptomatic stored episodes indicated no difference (p=NS) with respect to median ventricular rate (94 vs 94 bpm), atrial cycle length (230 vs 235 ms), or episode duration (103 vs 75 s). Conclusion: Over a long-term follow-up, the vast majority of AT/AF episodes are asymptomatic and patient symptoms are seldom associated with AT/AF episodes. Hence, patient symptoms are an unreliable index of recurrent AF in clinical studies of AF therapies and in management of anticoagulation therapy. Continuous monitoring via implantable device datalogs provides objective early and reliable detection of AF during followup.
1166-210
Silent Atrial Fibrillation: An Important Contributor to Total Burden of Atrial Fibrillation in Olmsted County, MN (1980 MN ( -1989 Marion E. Barnes, Yoko Miyasaka, A. Gabriela Rosales, Kent R. Bailey, James B. Seward, Bernard J. Gersh, Teresa S.M. Tsang, Mayo Clinic, Rochester, MN Background: There is a paucity of data on "silent" atrial fibrillation (AF). In this study, we aimed to estimate the prevalence of AF discovered incidentally in asymptomatic patients. Methods: The medical records for all adult residents of Olmsted County, MN, who had an ECG-confirmed diagnosis of first AF during 1980-89 were reviewed. Symptom presentation was classified as typical for AF, non-specific (symptoms present, but not classic for AF), or 'silent' (asymptomatic, AF detected incidentally). Results: A total of 801 (412 men, 389 women) residents (mean age, 72 ± 14 years, range 18-103 years) were documented to have the first episode of AF between 1980 and 1989. After exclusion of patients (n=186, 23%) with concurrent conditions that could have obscured AF symptoms (recent myocardial infarction (MI) or congestive heart failure (CHF)), and those in whom symptom data were not available (n=59, 7%), silent AF was identified in 193 (24%). The remaining 363 patients had symptoms at presentation (typical, n=186; non-specific symptoms, n=177). Clinical characteristics of those with silent AF versus those who presented with symptoms are detailed (Table) . In a multivariate model, age (P<0.001), male gender (P=0.007), slower AF rate (P<0.001), and history of MI(P=0.028) were independently related to silent AF.
Conclusion: 'Silent' AF accounts for a significant proportion of the total AF burden. Future studies to elucidate the outcomes for this subgroup of AF patients will be of immense public health importance. Magnesium did not have a significant effect on length of stay (weighted mean difference -0.07 days of stay, 95% Confidence interval -0.78, 0.63). The overall mortality was low (0.7%), and was not affected by magnesium administration (odds ratio 0.90, 95%CI 0.24; 3.32). Conclusion: Magnesium administration is an effective prophylactic measure for the prevention of postoperative atrial fibrillation. The magnitude of the effect of magnesium is similar to this of beta-blockers or amiodarone. Magnesium does not affect significantly length of stay or in-hospital mortality.
1166-211 Magnesium Effectively Prevents Postoperative Atrial Fibrillation in Patients After

1166-212 Pulmonary Vein Isolation in Patients With Prior Cardiac Surgery
Raed H. Abdelhadi, Jennifer Cummings, Oussama Wazni, Marc Gillinov, Andrea Natale, Nassir F. Marrouche, Cleveland Clinic Foundation, Cleveland, OH Background: Pulmonary vein isolation (PVI) has become a treatment option for patients with symptomatic atrial fibrillation (AF) resistant to medical therapy. The outcome of this procedure in patients who developed AF after cardiac surgery has not been established. Methods: Out of 454 patients who had PVI for symptomatic AF resistant to antiarrhythmic medication, we identified 36 patients with prior cardiac surgery who subsequently underwent PVI. The baseline characteristics and the recurrence rate in patients with prior cardiac surgery to the rest of the cohort.
Results:
Patients with cardiac surgery did not differ in their age (58 ± 10 vs. 54 ± 12 years), duration of AF (6.2 ± 3.2 vs. 5.9 ± 4.3 years), and length of follow up after PVI (456 ± 187 vs. 515±192 days). Patients with prior cardiac surgery had larger left atrial diameter (4.8 ± 1.2 vs. 4.1 ± 0.5 cm, P = 0.02), and lower left ventricular ejection fraction (47 ± 14 vs. 54 ± 11 %, P = 0.03). There was no significant difference in AF recurrence in patients with prior cardiac surgery compared to the rest of the cohort (11% vs. 18%, P = 0.9). Neither ejection fraction nor left atrial size predicted recurrence of AF. Conclusion: From our preliminary data, PVI seems to be feasible and effective even in patients with prior cardiac surgery. Therefore, history of cardiac surgery should not be considered an exclusion criterion for this procedure.
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